Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
AbstractPurpose of review
To describe some steps in the progress in the molecular biology of a peptide, apolipoprotein C3; its gene mutations that render individuals susceptible or resistant to developing hyperlipidaemia and atherosclerosis.Recent findings
Data that lead to the development of a new therapeutic agent volanesorsen.Summary
The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).